Co-Authors
This is a "connection" page, showing publications co-authored by Toni Choueiri and Brian Rini.
Connection Strength
2.328
-
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018 04; 19(4):451-460.
Score: 0.758
-
The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer. Cancer Cell. 2020 06 08; 37(6):738-741.
Score: 0.220
-
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 03 21; 380(12):1103-1115.
Score: 0.202
-
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2a Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2018 03 20; 36(9):867-874.
Score: 0.187
-
Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2017 06; 15(3):403-410.e2.
Score: 0.175
-
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer. 2011 Jun 15; 117(12):2637-42.
Score: 0.114
-
Care without a compass: Including patients with cancer in COVID-19 studies. Cancer Cell. 2021 07 12; 39(7):895-896.
Score: 0.059
-
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021 06; 32(6):787-800.
Score: 0.058
-
COVID-19 and Cancer: Current Challenges and Perspectives. Cancer Cell. 2020 11 09; 38(5):629-646.
Score: 0.057
-
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discov. 2020 10; 10(10):1514-1527.
Score: 0.056
-
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 06 20; 395(10241):1907-1918.
Score: 0.055
-
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 10; 20(10):1370-1385.
Score: 0.052
-
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 Dec; 24(12):1941.
Score: 0.050
-
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer. 2018 09 15; 124(18):3677-3683.
Score: 0.049
-
Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. Clin Genitourin Cancer. 2019 Feb; 17(1):65-71.
Score: 0.049
-
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 06; 24(6):749-757.
Score: 0.048
-
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 05; 378(14):1277-1290.
Score: 0.047
-
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol. 2017 Dec 10; 35(35):3916-3923.
Score: 0.046
-
Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). Kidney Cancer. 2017 Jul 26; 1(1):41-47.
Score: 0.045